secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001654954-23-004459
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience receives $1M bridge loan from CEO John Payne with 10% interest and warrants
--------------------------------------------------------------------------------

- CEO John Payne provides $1M unsecured six-month loan at 10% simple interest, extendable six months.
- Warrants to purchase 390,000 shares at $2.91 per share, exercisable for three years.
- Proceeds for working capital, coccidiosis validation study in broiler chickens, and strategic alternatives.
- Company expects to complete titration study in May 2023, then 42-day study in over 2,000 chickens by mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495423004459/0001654954-23-004459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495423004459/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-004459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer